The first EU Joint Clinical Assessment (JCA) has now been published, providing the first practical i...
Read moreThis on-demand session provides a concise update on recent developments in Most Favoured Nation (MFN...
Read moreAs Market Access continues to evolve amid policy reform, pricing pressure, and increasing evidence e...
Read moreNICE’s Highly Specialised Technologies (HST) Programme offers a vital route for bringing ultra-rar...
Read moreWhether you’re in drug development, market access, or health economics, early scientific advic...
Read moreRemap Consulting presents ground-breaking insights and practical learnings from one of the pioneerin...
Read moreRemap Consulting guides participants through the intricacies of incorporating EU HTA considerations ...
Read moreWebinar: Discussions on the new Voluntary Scheme for Branded Medicines, Pricing, Access and Growth (...
Read moreWebinar: Our experts discuss NICE's proportionate approach to technology appraisals and the implicat...
Read moreWebinar: Our experts discuss Orphan medicine market access in Europe including the impact of EU HTA ...
Read more